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Patients infected with the human immunodeﬁciency virus (HIV) are frequently exposed
to antimicrobial agents. This might have an impact on the resistance proﬁle, genetic
background and virulence factors of colonizing Staphylococcus aureus. Sub-Saharan Africa
is considered to be endemic for Panton-Valentine leukocidin (PVL) positive S. aureus which
can be associated with skin and soft tissue infections (SSTI).We compared S. aureus from
nasal and pharyngeal swabs from HIV patients (n = 141) and healthy controls (n = 206)
in Gabon in 2013, and analyzed determinants of colonization with PVL positive isolates in
a cross-sectional study. S. aureus isolates were screened for the presence of selected
virulence factors (incl. PVL) and were subjected to antimicrobial susceptibility testing and
genotyping. In HIV patients, S. aureus was more frequently detected (36.9 vs. 31.6%) and
the isolatesweremore frequently PVL positive than in healthy controls (42.1 vs. 23.2%).The
presence of PVL was associated with cotrimoxazole resistance (OR = 25.1, p < 0.001)
and the use of cotrimoxazole was a risk factor for colonization with PVL positive isolates
(OR = 2.5, p = 0.06). PVL positive isolates were associated with the multilocus sequence
types ST15 (OR = 5.6, p < 0.001) and ST152 (OR = 62.1, p < 0.001). Participants colonized
with PVL positive isolates reported more frequently SSTI in the past compared to carriers
of PVL negative isolates (OR = 2.7, p = 0.01). In conclusion, the novelty of our study is that
cotrimoxazole might increase the risk of SSTI in regions where cotrimoxazole resistance is
high and associated with PVL. This ﬁnding needs to be conﬁrmed in prospective studies.
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INTRODUCTION
Staphylococcus aureus is a bacterial pathogen causing a broad
range of infections such as skin and soft tissue infections (SSTI),
osteomyelitis, pneumonia, and endocarditis (Wertheim et al.,
2005). Nasal colonization often precedes invasive infection which
is frequently caused by the homolog isolate of the anterior nares
(von Eiff et al., 2001). Therefore, nasal colonization rates and
molecular characterization of colonizing isolates provide impor-
tant insights into the risk of S. aureus infection in selected human
populations. A recent study showed that impairment of the
immune system by the human immunodeﬁciency virus (HIV)
increases the risk for S. aureus colonization (Olalekan et al., 2012).
In the present study we compare S. aureus from HIV patients
and healthy controls as S. aureus belongs to the most relevant
pathogens of both superﬁcial and invasive infections in Africa
(Reddy et al., 2010; Alabi et al., 2013).
Staphylococcus aureus possess an armory of different viru-
lence factors (Otto, 2014b). The Panton-Valentine leukocidin
(PVL) is one of the most prevalent virulence determinant in S.
aureus in sub-Saharan Africa (Schaumburg et al., 2014b). PVL
is a bi-component protein toxin that binds to the complement
receptor C5a of neutrophils (Spaan et al., 2013). This leuko-
cidin shows strong cytotoxicity on granulocytes and can be
associated with severe SSTI (Shallcross et al., 2013). However,
its role in pathogenesis in humans remains controversial (Otto,
2014b).
Sub-Saharan Africa suffers from the highest burden of HIV
infections in the world; 68% of all infected persons reside
in this region, which only accounts for 12% of the global
population (World Health Organization, 2011). Cotrimoxazole
(trimethoprim-sulfamethoxazole) prophylaxis has been shown
to lower mortality in HIV infected patients through reduced
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rates of Pneumocystis jirovecii pneumonia, malaria, and bacte-
rial infections (Suthar et al., 2012; Bwakura-Dangarembizi et al.,
2014). However, cotrimoxazole is also a broad spectrum antibac-
terial drug which might impact on S. aureus colonization of HIV
patients particularly in long-term use. Cotrimoxazole inhibits
the folate biosynthesis by blocking the dihydropteroate syn-
thase (DHPS, sulfamethoxazole) and the dihydrofolate reductase
(DHFR, trimethoprim; Lyon and Skurray, 1987). Cotrimoxa-
zole resistance is caused by mutations of the genes encoding
the DHPS and/or DHFR or the acquisition of mutated genes
through horizontal gene transfer (Lyon and Skurray, 1987). A
recent study showed that the DHFR gene dfrG is the major cause
of trimethoprim resistance in sub-Saharan Africa (Nurjadi et al.,
2014).
In the present study, we (i) compared S. aureus isolates from
HIV positive patients with those from healthy controls and (ii)
analyzed determinants of colonization with PVL positive isolates.
These study objectives are novel as they address for the ﬁrst time
determinants of colonization with PVL positive S. aureus in Africa




Ethical approval was obtained from the institutional review board
of the “Centre de Recherches Médicales de Lambaréné” in Gabon
(CEI 004/2013). Written informed consent was signed by all
participants before enrollment.
STUDY DESIGN
The primary objective of the study was to compare resistance rates
and virulence factors of S. aureus from HIV patients with those
from healthy controls. The secondary objective was to identify risk
factors for the colonization with PVL positive isolates.
A recent study from Nigeria showed mean resistance rates to
antimicrobial agents (i.e., cotrimoxazole, chloramphenicol, and
ciproﬂoxacin) in S. aureus from HIV positive patients and healthy
controls of 51.7 and 23.7%, respectively (Olalekan et al., 2012).
A sample size calculation assuming these mean resistance rates,
a power of 0.8 and an alpha of 0.05 gave a total of 53 isolates
per group. Assuming an average colonization rate of 37% in HIV
positive patients and 25% in healthy people yielded a sample size
of 143 HIV patients and 212 healthy controls (Shet et al., 2009;
Olalekan et al., 2012; Kotpal et al., 2014).
Participants were recruited from the Lambaréné region in
Gabon between March and September 2013 if they met the inclu-
sion criteria of (i) providing written informed consent and (ii) age
≥18 years. Subjects with culture conﬁrmed S. aureus infections at
enrollment were excluded from the ﬁnal analysis.
Human immunodeﬁciency virus positive patients attending
one of the three out-patient clinics in Lambaréné (Hôpital Albert
Schweitzer, Hôpital Régional George Rawiri, Centre de Traitement
Ambulatoire) were recruited. Healthy controls were recruited in
Lambaréné and surrounding villages.
An HIV test was offered to each participant to verify the HIV
status. Demographic data (sex, age), medical history (hospitaliza-
tion, use of antibiotics in the past 6 months, history of SSTIs),
were documented in a standardized questionnaire. The patient’s
information was derived from records of the personal health care
ﬁles and interviews.
HIV TEST AND CD4+ CELL COUNT
Human immunodeﬁciency virus status was assessed using rapid
tests (Determine HIV1/2, Abbott Laboratories, Tokyo, Japan or
Vikia, bioMérieux, Marcy l’Etoile, France). T-helper cells [cluster
of differentiation four positive cells (CD4+ cells)] were measured
in venous EDTA blood using FACSCount (BD Biosciences, San
Jose, CA, USA).
BACTERIAL ISOLATES
At enrollment, one nasal swab was taken by swabbing gently the
mucosa of both anterior nares (including the nasal septum) for few
secondswith rotatingmovements (Schaumburg et al., 2014a). One
pharyngeal swab was taken by swabbing the posterior pharyngeal
wall with horizontal movements (Schaumburg et al., 2014a). Cot-
ton tips were stored in Amies medium (Transwabs, Medical Wire,
Corsham, UK) and cultured within 3 h for 24–48 h on Columbia
blood agar supplemented with aztreonam disks (13 μg; Oxoid,
Hants, UK; Schaumburg et al., 2014a).
Colonies were tested for positive catalase and agglutination test
(Pastorex, Staph-Plus; Bio-RadLaboratories,Marnes-la-Coquette,
France). Species identiﬁcation and antimicrobial susceptibility test
(EUCAST clinical breakpoints) were done using Vitek 2 auto-
mated systems (bioMérieux). Species was conﬁrmed by the PCR
detection of the thermostable nuclease nuc (Brakstad et al., 1992).
Methicillin resistance was conﬁrmed by the PCR detection of the
penicillin binding protein 2a (PBP2a) encoding genemecA (Becker
et al., 2006). All MRSA were screened for the arginine catabolic
mobile element (ACME; Diep et al., 2006).
Genes encoding the exfoliative toxins, pyrogenic toxin super-
antigens (i.e., enterotoxins, toxic shock syndrome toxin) and the
Panton-Valentine leukocidin (PVL) were detected by PCR (Lina
et al., 1999; Becker et al., 2003).
If a participant was colonized with an identical isolate [based
on spa typing (Mellmann et al., 2006)] in the nose and throat, only
one isolate was included in the ﬁnal analysis of resistance rates and
virulence factors in order to report non-duplicate isolates only.
GENOTYPING
All isolates were S. aureus protein A (spa) typed based on the
sequence of the hypervariable region of protein A (Mellmann
et al., 2006). One isolate of each spa type was subjected to multilo-
cus sequence typing (MLST; Enright et al., 2000) and each MLST
sequence type (ST) was assigned to MLST clonal complexes (CC)
using eBURST1.
STATISTICS
Colonization was deﬁned as detection of S. aureus in the anterior
nares and/or pharynx. The χ2- and Fisher exact tests and logistic
regression analyses were used to assess the association of HIV
status with demographic characteristics and molecular features
of S. aureus (e. g. antimicrobial resistance, virulence factors), to
estimate odds ratio (OR), the 95% conﬁdence intervals (95% CI)
1http://saureus.mlst.net; hosted at the Imperial College, London
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and to adjust for potential confounders. The signiﬁcance level was
set at 0.05. Mean values are shown ± SD. Statistical analysis was
performed with “R” and the package “epicalc2.”
To test if statistical associations of the present study could
be reproduced, we used a database including 469 non-duplicate
isolates (based on spa typing) from healthy, HIV negative,
asymptomatic volunteers collected during earlier studies in the
Lambaréné region (Schaumburg et al., 2013, 2014a).
RESULTS
STUDY POPULATION
In total, 348 participants were recruited; one HIV positive patient
was excluded due to a culture conﬁrmed S. aureus wound infection
at inclusion. Therefore, 141 HIV positive participants and 206
healthy controls were included in the ﬁnal analysis.
All participants in the HIV group were conﬁrmed to be HIV
positive. The median (range) CD4+ cell count was 166 (2-1374)
cells/μl. In total, 49 HIV patients (34.8%) were on antiretroviral
therapy at the time of inclusion.
In the control group, 68% (n = 140) were HIV negative, 26.9%
(n = 56) had a negative test result within the last 3 months but
refused a conﬁrmatory test, and 4.9% (n = 10) did not report any
test results but refused to be tested for HIV.
COMPARISON OF S. aureus COLONIZATION BETWEEN HIV PATIENTS
AND HEALTHY CONTROLS
On average, participants in both comparison groups were of the
same age (Table 1). However, HIV positive subjects were more
often female and reported more health care contacts within the
past 6 months compared to healthy controls (Table 1). HIV
patients signiﬁcantly used more antimicrobial agents than healthy
controls in the past 6 months; such as cotrimoxazole (including
cotrimoxazole prophylaxis, 34.0 vs. 1.5%, OR = 33.3, 95% CI:
11.1–100.0, p< 0.001), amoxicillin/clavulanic acid (22.7 vs. 8.3%,
OR = 3.2, 95% CI: 1.7–6.7, p < 0.001) and ciproﬂoxacin (9.9 vs.
1.5%, OR = 7.7, 95% CI: 2.0–50.0, p = 0.001). No association of
S. aureus colonization and CD4+ cell count was detected (data not
shown).
2http://cran.r-project.org
Staphylococcus aureus colonization was associated with HIV
positive participants but did not reach statistical signiﬁcance
(Table 1). This association remained stable when adjusting car-
riage for history of pyodermatitis, hospitalization and use of
antibiotics in the past 6 months (adjusted OR = 0.8, 95% CI:
0.5–1.2, p = 0.3).
In total, 125 non-duplicate isolates from HIV patients (n = 56)
and healthy controls (n = 69) were included in the ﬁnal analysis.
Compared to healthy controls, resistance rates of cotrimoxazole
were slightly higher in isolates from HIV patients, but did not
reach statistical signiﬁcance (Table 2). The distribution of resis-
tance rates of other tested antimicrobial agents was similar in
both groups (Table 2). No resistance was detected against clin-
damycin, linezolid, fosfomycin, fusidic acid, and glycopeptides.
For tested virulence factors, PVL was more frequently detected
in isolates from HIV patients compared to healthy controls (42.9
vs. 23.2%, Table 2). Genes encoding other virulence factors such
as the enterotoxins sea, seg, and sec, the exfoliative toxin a (eta)
and the toxic shock syndrome toxin (tst) were equally distributed
among both groups.
The MRSA isolates belonged to spa types t121 (n = 1, ST8, PVL
positive, ACME positive), t451 (n = 1, ST8, PVL negative, ACME
positive), t1476 (n = 1, ST6, PVL negative, ACME negative) and
t12858 (n = 2, PVL negative, ACME positive). Table 3 shows the
distributionof genotypes in all S. aureus isolates fromHIVpatients
and healthy controls.
DETERMINANTS OF COLONIZATION WITH PVL POSITIVE S. aureus
We now addressed potential variables for the colonization with
PVL positive S. aureus and hypothesized that the use of antimicro-
bial agents might select for PVL positive isolates. For this purpose,
we merged isolates from HIV patients and healthy controls. PVL
positive isolates were signiﬁcantly associated with cotrimoxazole
resistance (Table 4). Use of cotrimoxazole was signiﬁcantly asso-
ciated with cotrimoxazole resistance (OR = 3.3, 95% CI: 1.0–12.4,
p = 0.03). This was in line with an association of cotrimoxazole
use and the detection of PVL positive isolates but did not reach
statistical signiﬁcance (Table 4). PVL positive isolates belonged
more likely to ST15 and ST152 (Table 4). Cotrimoxazole resis-
tance was strongly associated with ST15 (OR = 18.4, 95% CI:
Table 1 | Baseline characteristics of the study population.
HIV positive participants (n = 141)a Healthy controls (n = 206)a OR (95% CI) p
Age, mean ± SD 38.7 ± 11.1 37.5 ± 15.5 1 (1.0–1.0) 0.4
Sex, female 102 (72.3%) 120 (58.3%) 1.8 (1.2–2.9) 0.01
Hospitalization in the past 6 months 95 (67.4%) 46 (22.3%) 0.1 (0.1–0.2) <0.001
Antibiotics in the past 6 months 107 (75.9%) 61 (29.6%) 0.1 (0.1–0.2) <0.001
Pyodermatitis 29 (20.6%) 13 (6.3%) 0.3 (0.1–0.6) <0.001
S. aureus colonization 52 (36.9%) 65 (31.6%) 0.8 (0.5–1.2) 0.3
Nasal S. aureus colonization 36 (25.5%) 40 (19.4%) 0.7 (0.4–1.2) 0.2
Pharyngeal S. aureus colonization 29 (20.6%) 37 (18.0%) 0.8 (0.5–1.4) 0.5
Data are n (%) of subjects unless otherwise indicated, OR (95%CI) and p-value derived from logistic regression analysis.
aA pharyngeal swab was refused by three HIV positive participants and one control.
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Table 2 | Characteristics of Staphylococcus aureus in HIV patients and healthy controls, Gabon.
S. aureus, n (%) OR (95%CI) P
HIV positive participants (n = 56) Healthy controls (n = 69)
Antimicrobial resistance Penicillin 52 (92.9%) 66 (95.7%) 0.6 (0.1–3.7) 0.5
Oxacillin 3 (5.4%) 2 (2.9%) 1.9 (0.2–23.4) 0.7
Erythromycin 4 (7.1%) 10 (14.5%) 0.5 (0.1–1.7) 0.3
Gentamicin 1 (1.8%) 1 (1.5%) 1.2 (0.0–98.4) 1
Tetracyclin 26 (46.4%) 30 (43.5%) 1.1 (0.5–2.4) 0.7
Cotrimoxazole 32 (57.1%) 33 (47.8%) 1.4 (0.7–3.3) 0.3
Virulence factors lukS-PV/lukF -PV (PVL) 24 (42.9%) 16 (23.2%) 2.5 (1.1–5.9) 0.02
sea 18 (32.1%) 17 (24.6%) 1.5 (0.6–3.5) 0.4
seg 15 (26.8%) 22 (31.9%) 0.8 (0.3–1.8) 0.5
sec 6 (10.7%) 6 (8.7%) 1.3 (0.3–5) 0.7
eta 2 (3.6%) 1 (1.5%) 2.5 (0.1–100) 0.6
tst 3 (5.4%) 3 (4.4%) 1.3 (10) 1
Table 3 | Genotypes of Staphylococcus aureus isolates from HIV patients and healthy controls, in Gabon in 2013.
CC ST Isolates from HIV-positive participants (n = 56) Isolates from healthy controls (n = 69) OR (95% CI)a Pa
S. aureus spa types (n) Total S. aureus spa types (n) Total
CC5 ST1 t127 (1) 64.9% t127 (3), t4448 (1) 72.1% 1.32 (0.58–3.01) 0.5
ST5 t5987 (1) t319 (3), t1400 (2), t5987 (4)
ST6 t701 (1), t1476 (3) t304 (1), t701 (1), t1476 (4)
ST8 t121 (1), t064 (1), t12858 (2) t451 (1), t1476 (2)
ST9 t1045 (1) t1045 (1)
ST15 t084 (15), t094 (1), t491 (2), t803 (1) t084 (12), t085 (1), t279 (2), t12523 (1)
ST72 t148 (3) t148 (3), t2464 (1), t11108 (1)
ST188 t189 (1) t189 (1)
ST573 t1579 (1) –
ST2708 t311 (1) t311 (3)
ST2736 – t254 (1)
ST2765 t11644 (1) –
CC45 ST45 t939 (2) 7.0% t12857 (1) 4.4% 0.6 (0.08−3.74) 0.7
ST508 t015 (1), t073 (1) t12525 (1)
ST2498 – t827 (1)
CC101 ST101 t056 (1) 1.8% t056 (4), t3165 (1), t4679 (2) 10.3% 6.32 (0.76−289.54) 0.07
CC152 ST152 t355 (10) 17.5% t355 (8) 11.8% 0.62 (0.2−1.9) 0.3
Other ST7 t091 (1) 8.8% – 1.5% 0.31 (0.03−2.01) 0.2
ST88 t12856 (1) t2723 (1)
ST121 t645 (1) –
ST2349 t026 (1) –
ST1223 – NT (1)
PVL, positive spa types in bold. aComparison of the proportion of clonal complexes (CC).
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Table 4 | Determinants of colonization with PVL positive S. aureus.
Characteristics PVL positive S.
aureus (n = 40)
PVL negative S.






Use of antimicrobials 26 (65.0%) 36 (42.4%) 2.5 (1.1–6.0) 0.02 2.0 (0.8–4.6) 0.13
Cotrimoxazole usea 10 (25.0%) 10 (11.8%) 2.5 (0.8–7.4) 0.06
Abscessa 11 (27.5%) 13 (15.3%) 2.1 (0.8–5.7) 0.1
Any SSTIa,b 20 (50.0%) 23 (27.1%) 2.7 (1.1–6.3) 0.01 2.6 (1.2–5.7) 0.02
Cotrimoxazole resistance 37 (92.5%) 28 (32.9%) 25.1
(6.9–134.4)
<0.001 26.0 (7.2–93.8) <0.001
S. aureus ST15 21 (52.5%) 14 (16.5%) 5.6 (2.2–14.2) <0.001 5.4 (2.3–12.7) <0.001





Data are n (%) of subjects. SSTI, skin and soft tissue infection. Eight carriers were colonized with two different isolates resulting in 125 isolates from 117 colonized
individuals. a in the past 6 months. bany SSTI: wound infection, carbuncle/furuncle, abscess, pyodermatitis, cadjusted for HIV infection.
5.1–99.0, p < 0.001) and ST152 (OR = 5.7, 95% CI: 1.5–32.1,
p = 0.004). The colonization with either of these genotypes were
more common in HIV positive patients compared to healthy con-
trols (OR = 2.0, 95% CI: 0.9–4.4, p = 0.06) and in participants
reporting use of cotrimoxazole (OR = 2.3, 95% CI: 0.8, 7.2,
p = 0.08).
Of note, participants colonized with PVL positive S. aureus
reported more frequently any type of SSTIs (pyodermati-
tis, abscess, furuncle/carbuncle, wound infection) in the past
6 months than those colonized with other isolates (Table 4).
As HIV infection might be a confounder in our dataset we per-
formed a multivariate analysis and adjusted those association for
HIV status which were statistically signiﬁcant in the univariate
analysis. HIV infection was a weak confounder of the association
between the use of antimicrobials and the detection of PVL pos-
itive isolates (Table 4). The associations between PVL and SSTI,
cotrimoxazole resistance, ST15 and ST152 remained stable after
adjusting for HIV status.
As cotrimoxazole resistant isolateswere associatedwithPVL,we
analyzed the association of different exposure variables with the
combined outcome“PVLpositivity and cotrimoxazole resistance.”
This combined outcome was also signiﬁcantly associated with the
exposure “use of antimicrobial agents” (OR = 2.4, 95% CI: 1.1–
5.4, p = 0.03) and “SSTI” (OR = 2.4, 95% CI: 1.1–5.3, p = 0.03)
in the past 6 months.
ASSOCIATION OF PVL POSITIVITY AND COTRIMOXAZOLE RESISTANCE
IN A RETROSPECTIVE STRAIN COLLECTION
We now tested if our ﬁndings could be reproduced analyzing an
already existing strain collection of 469 non-duplicate isolates
from healthy, HIV negative, asymptomatic volunteers from ear-
lier studies in the Lambaréné region (Schaumburg et al., 2013,
2014a). Here, we also found strong evidence for an association of
cotrimoxazole resistance with the presence of PVL in colonizing S.
aureus (OR = 5.9, 95% CI: 3.7–9.1, p< 0.001) and with the geno-
types ST152 or ST15 (OR = 14.3, 95%CI: 9.1–25.0, p < 0.001,
Table S1).
DISCUSSION
Our study found an association of PVL positive isolates with the
use of cotrimoxazole and cotrimoxazole resistance. These ﬁnd-
ings suggest a selection of cotrimoxazole resistant PVL positive
S. aureus clones through the use of cotrimoxazole. Use of cotri-
moxazole might therefore put individuals at higher risk for SSTI in
regions where cotrimoxazole resistance is high and associated with
PVL. This might be particularly true for HIV patients receiving
long term cotrimoxazole prophylaxis.
The higher proportion of females in the HIV group has been
reported by others as well and might either reﬂect a higher risk
for HIV infection in females (Olalekan et al., 2012) or gender
differences in the overall willingness to participate in research
that requires disclosure of HIV status. We detected higher S.
aureus colonization rates in HIV patients compared to healthy
controls, which is in line with a recent report from Nige-
ria (Olalekan et al., 2012) and a 3–7 fold higher prevalence of
HIV infection in adult women compared to men (Karim et al.,
2010).
It is well established that the use of antimicrobial agents
selects for resistant isolates (Monroe and Polk, 2000; van de
Sande-Bruinsma et al., 2008). Therefore, it is not surprising that
cotrimoxazole resistance is higher in African HIV patients who
are more frequently exposed to cotrimoxazole, as shown in our
study. However, cotrimoxazole is also amongst themost frequently
used antimicrobial compounds in the general population which
explains the high cotrimoxazole resistance in Gabon and other
regions of Africa (up to 55% in colonizing isolates; Schaumburg
et al., 2014b).
We showed that the use of cotrimoxazole is a risk factor for
colonization with PVL positive and cotrimoxazole resistant ST15
and ST152 isolates. These two lineages are the major PVL pos-
itive clones in sub-Saharan Africa (Schaumburg et al., 2014b).
Co-occurrence of cotrimoxazole resistance with PVL or with the
MLST genotypes ST15 and ST152 was conﬁrmed by reanalyz-
ing published data from healthy asymptomatic carriers in Gabon
(Schaumburg et al., 2013, 2014a). It is possible that this ﬁnding can
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be extrapolated to other African regions where PVL is associated
with cotrimoxazole resistance as well (Breurec et al., 2011).
Altogether, our analysis suggests the following model: cotri-
moxazole resistance co-occurs with PVL. The use of cotrimoxazole
selects for cotrimoxazole resistant isolates which are frequently
PVL positive. The possession of PVL and most likely other
virulence factors might pose a risk for SSTI.
However, it remains unclear why cotrimoxazole resistance is
co-detected with PVL. One might speculate that genes encod-
ing PVL and cotrimoxazole resistance are carried by the same
bacteriophage which has transferred both determinants to the
bacterial host genome particularly to S. aureus belonging to
ST15 and ST152. One might then expect that both genes are
located in close proximity to each other. However, to the best
of our knowledge, no PVL bacteriophage has been described
which also carries antimicrobial resistance genes. Only one
novel PVL bacteriophage has been reported which also carried
the enterotoxin a gene (sea; Prabhakara et al., 2013). Whole
genome sequencing should be performed in future (i) to map
the genes of PVL and cotrimoxazole resistance in the bacte-
rial genome and (ii) to assess if both are carried by the same
bacteriophage.
Despite these ﬁndings we would like to point out that cotri-
moxazole prophylaxis should not be discouraged in HIV patients
as the beneﬁt has been clearly shown (Suthar et al., 2012; Bwakura-
Dangarembizi et al., 2014), and as clinical implications of PVL are
still controversial (Otto, 2014b). The implication of our study on
HIV patients’ care is to sensitize physicians for the counselling on
and the early detection of SSTI in patients receiving cotrimoxazole
prophylaxis. A higher risk of SSTI in these patients might be possi-
ble as our analysis revealed an association of PVL positive isolates
with a history of SSTI in the past 6 months that was independent
of the HIV status. In addition, a strong association of PVL with
SSTIs was also recently shown by a large meta-analysis (Shallcross
et al., 2013).
However, PVL is not the only virulence factor which can be
associated with SSTIs. Strong tissue toxicity has also been shown
for theα-toxin or the phenol-solublemodulins (Becker et al., 2014;
Otto, 2014a).
Our study is limited by our small sample size and an unknown
HIV status of 10 (4.9%) participants. We believe that the risk of
miss-including HIV positive patients in the control group is low
as the HIV prevalence was low in Gabon in 2009 (5.2%, declining
trend) compared to South and East Africa (World Health Orga-
nization, 2011). In addition these participants were not followed
by any of the HIV clinics in Lambaréné. Second, the setting of
the recruitment was not the same for HIV positive patients (clin-
ics) and controls (community setting). As only healthy controls
should be included, we were not able to recruit them in the hos-
pital setting. Third, the cross-sectional study design cannot detect
the causality of high prevalence of PVL positive isolates. We only
are able to identify potential factors causing a selection of PVL
positive isolates which might be addressed in future prospective
studies.
In conclusion, cotrimoxazole use was associated with PVL
positive and cotrimoxazole-resistant S. aureus. Therefore, cot-
rimoxazole prophylaxis may put HIV patients at risk of SSTIs
in regions where cotrimoxazole resistance is high and associated
with PVL.
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